Neuropathy clinical trials at UCSF
2 in progress, 1 open to eligible people
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
open to eligible people ages 25 years and up
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
San Francisco, California and other locations
Laryngopharyngeal Sensation: Cancer Survivor Cohort
Sorry, not yet accepting patients
A previous study completed in 2022 (NCT05158179) was conducted using cohorts of healthy controls, and adults with general laryngopharyngeal disorders. This study will expand on the previous research to include a separate cohort of adults being seen in clinic for an existing laryngopharyngeal disorder resulting from previous radiation or other cancer treatments.
San Francisco, California
Our lead scientists for Neuropathy research studies include Terence W. Friedlander Yue Ma, MD.
Last updated: